Compare SEZL & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SEZL | LIVN |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | 3300 |
| Industry | Diversified Financial Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.3B |
| IPO Year | 2023 | 2015 |
| Metric | SEZL | LIVN |
|---|---|---|
| Price | $110.86 | $78.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $109.33 | $72.43 |
| AVG Volume (30 Days) | 361.9K | ★ 521.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.64 | 2.33 |
| Revenue | ★ $450,279,000.00 | N/A |
| Revenue This Year | $30.30 | $9.79 |
| Revenue Next Year | $24.79 | $6.63 |
| P/E Ratio | $44.15 | ★ $33.55 |
| Revenue Growth | ★ 66.08 | N/A |
| 52 Week Low | $49.50 | $48.82 |
| 52 Week High | $195.71 | $85.76 |
| Indicator | SEZL | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 48.56 |
| Support Level | $112.53 | $77.28 |
| Resistance Level | $122.31 | $82.39 |
| Average True Range (ATR) | 4.60 | 1.94 |
| MACD | 0.94 | -0.17 |
| Stochastic Oscillator | 37.90 | 33.61 |
Sezzle Inc is a financing institution that offers technology-driven payment platform. The Sezzle Platform offers a payments solution for consumers in the United States and Canada that has the ability to instantly extend credit at the point-of-sale, allowing consumers to purchase and receive merchandise while paying in installments over time. Consumers pay a portion of the purchase price at the point-of-sale as a down payment, and then pay off the remaining amount over time through scheduled payments. It also offer the ability to pay-in-full using the Sezzle Platform. Its operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.